Paolo Prandoni

University of PaduaItaly

Prof Paolo Prandoni Biography Title: Full Professor Institution: Department of Cardiothoracic and Vascular Sciences, Chief of the Clinica Medica 2, University of Padova, Via Giustiniani, 2, 35128 – Padova (Italy) Education/Training 1971 M.D. degree University of Padova 1974 Hematology Residency University of Padova, Italy 1976 Internal Medicine Residency University of Padova 1979 Cardiology Residency University of Padova 1992 Ph.D. University of Amsterdam Positions 1980 University Researcher University of Padova 2000 Associate Professor University of Padova 2006 Full Professor University of Padova Titles 1995 Visiting Professor of the Harvard Medical School (Boston, USA) 2008 Member of the Council of the Mediterranean League against Thromboembolic Diseases 2009 Member of the American College of Chest Physicians for the delivery of international guidelines for the treatment of venous thromboembolic disorders. Research and Professional Experiences Epidemiology, diagnosis and management of venous thromboembolism. Of particular interest are studies addressing the association of cancer with venous thromboembolism. Professor Prandoni has published more than 300 papers in peer-review journals. My main achievements were: 1. The demonstration of the value of real-time compression ultrasonography for the diagnosis of DVT (NEJM 1989) 2. the confirmation of the risk for subsequent overt cancer in patients with idiopathic VTE (NEJM 1992) 3. the demonstration that LMWHs are as effective and safe as UFH in the treatment of DVT (Lancet 1992) 4. the demonstration that LMWHs allow the home treatment of DVT (NEJM 1996) 5. the description of the natural history of DVT, outlining the particularly high risk of recurrent thromboembolism in cancer patients (Ann Intern Med 1996) 6. the demonstration that both factor V Leiden and G20210A prothrombin variant are independent risk factors for recurrent VTE (NEJM 1997, Blood 2000). 7. the demonstration that residual vein thrombosis is a predictive marker of recurrent thromboembolism (Ann Intern Med 2002) 8. the demonstration that cancer patients with venous thrombosis have a high risk of recurrent thromboembolism while on anticoagulation (Blood 2003) 9. the demonstration of an association between atherosclerosis and venous thrombosis (NEJM 2003) 10. the demonstration that chronic pulmonary thromboembolic hypertension following an episode of pulmonary embolism is more frequent than commonly thought (NEJM 2004) 11. the demonstration that tailoring the duration of anticoagulation according to the persistence of residual vein thrombi reduces the risk of recurrent Thromboembolism (Ann Intern Med 2009) 12. the demonstration that fondaparinux is effective and safe for the treatment of superficial vein thrombosis in the legs (N Engl J Med 2010

1chapters authored